These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28645562)

  • 1. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
    de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
    Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
    Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
    Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
    Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
    Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of JAK inhibitors in multiple myeloma.
    Ghermezi M; Spektor TM; Berenson JR
    Clin Adv Hematol Oncol; 2019 Sep; 17(9):500-505. PubMed ID: 31549971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
    Monaghan KA; Khong T; Burns CJ; Spencer A
    Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma.
    Berenson JR; To J; Spektor TM; Martinez D; Turner C; Sanchez A; Ghermezi M; Eades BM; Swift RA; Schwartz G; Eshaghian S; Stampleman L; Moss RA; Lim S; Vescio R
    Clin Cancer Res; 2020 May; 26(10):2346-2353. PubMed ID: 31937615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
    Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
    Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.
    Chen H; Li M; Sanchez E; Soof CM; Bujarski S; Ng N; Cao J; Hekmati T; Zahab B; Nosrati JD; Wen M; Wang CS; Tang G; Xu N; Spektor TM; Berenson JR
    Br J Haematol; 2020 Jan; 188(2):283-294. PubMed ID: 31423579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
    Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
    Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
    Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
    Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
    Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
    Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro.
    Wilson GS; Tian A; Hebbard L; Duan W; George J; Li X; Qiao L
    Cancer Lett; 2013 Dec; 341(2):224-30. PubMed ID: 23941832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.
    Sanchez E; Li M; Patil S; Soof CM; Nosrati JD; Schlossberg RE; Vidisheva A; Tanenbaum EJ; Hekmati T; Zahab B; Wang C; Tang G; Chen H; Berenson JR
    Ann Hematol; 2019 Mar; 98(3):691-703. PubMed ID: 30635766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of vincristine sensitivity in retinoblastoma through Janus kinase inhibition by ruxolitinib.
    Ke F; Wang N; Zhang X; Liu R; Ren T; Ke J; Yang J; Yan H; Ma J
    Anticancer Drugs; 2024 Aug; 35(7):615-622. PubMed ID: 38742728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
    Tang S; Cheng B; Zhe N; Ma D; Xu J; Li X; Guo Y; Wu W; Wang J
    Anticancer Drugs; 2018 Jan; 29(1):61-74. PubMed ID: 29049036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
    Guo HM; Sun L; Yang L; Liu XJ; Nie ZY; Luo JM
    Oncol Rep; 2018 Jun; 39(6):2873-2880. PubMed ID: 29693175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
    Mesa RA
    IDrugs; 2010 Jun; 13(6):394-403. PubMed ID: 20506062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
    Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
    Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.